Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Authors
Keywords
-
Journal
Lancet Gastroenterology & Hepatology
Volume 8, Issue 2, Pages 179-191
Publisher
Elsevier BV
Online
2023-01-06
DOI
10.1016/s2468-1253(22)00338-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
- (2022) Christophe E. M. De Block et al. DIABETES OBESITY & METABOLISM
- Is calorie restriction beneficial for normal-weight individuals? A narrative review of the effects of weight loss in the presence and absence of obesity
- (2022) Faidon Magkos NUTRITION REVIEWS
- Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
- (2022) Alessandro Mantovani et al. Lancet Gastroenterology & Hepatology
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
- (2022) Thomas Karagiannis et al. DIABETOLOGIA
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss
- (2022) Berit Østergaard Christoffersen et al. Obesity
- Tirzepatide adds hepatoprotection to its armoury
- (2022) Giovanni Targher Lancet Diabetes & Endocrinology
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
- (2022) Linda Henry et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
- (2022) Fuxun Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
- (2022) Monica Imbernon et al. Cell Metabolism
- Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
- (2022) Julian M Yabut et al. ENDOCRINE REVIEWS
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
- (2022) Kiarash Riazi et al. Lancet Gastroenterology & Hepatology
- Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
- (2021) Joanna Michałowska et al. Nutrients
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Non-alcoholic fatty liver disease
- (2021) Elizabeth E Powell et al. LANCET
- The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
- (2021) Giovanni Targher et al. Nature Reviews Gastroenterology & Hepatology
- Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
- (2021) Giovanni Targher et al. Lancet Gastroenterology & Hepatology
- Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism
- (2021) Diba Borgmann et al. Cell Metabolism
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Amplifying the antidiabetic actions of glucagon‐like peptide‐1: Potential benefits of new adjunct therapies
- (2021) Neil Tanday et al. DIABETIC MEDICINE
- Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1
- (2021) Yizhong Peng et al. FREE RADICAL BIOLOGY AND MEDICINE
- The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
- (2021) Tom H Karlsen et al. LANCET
- The emerging role of incretins and twincretins
- (2021) Elaine Chow et al. Nature Reviews Endocrinology
- Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
- (2021) Giulio Marchesini et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
- (2021) Nazi Song et al. Acta Pharmaceutica Sinica B
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
- (2020) Eleonora Scorletti et al. GASTROENTEROLOGY
- Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2020) Ling-Yun Zhang et al. Clinics and Research in Hepatology and Gastroenterology
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- On adaptive thermogenesis: just another weight-loss tale?
- (2020) Faidon Magkos AMERICAN JOURNAL OF CLINICAL NUTRITION
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
- (2020) Manal Abdelmalek et al. JOURNAL OF HEPATOLOGY
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice
- (2020) Shilpak Bele et al. eLife
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation
- (2019) Maurice B. Bizino et al. DIABETOLOGIA
- Glucagon-like peptide 1 in health and disease
- (2018) Andreas Andersen et al. Nature Reviews Endocrinology
- The Origin and Understanding of the Incretin Concept
- (2018) Jens F. Rehfeld Frontiers in Endocrinology
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- The Efficacy of Energy-Restricted Diets in Achieving Preoperative Weight Loss for Bariatric Patients: a Systematic Review
- (2018) Fathimath Naseer et al. OBESITY SURGERY
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
- (2017) Giovanna Muscogiuri et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity
- (2016) Faidon Magkos et al. Cell Metabolism
- Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
- (2016) Roy Eldor et al. DIABETES CARE
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- Novel extrapancreatic effects of incretin
- (2016) Yuichiro Yamada et al. Journal of Diabetes Investigation
- Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
- (2015) Giuseppe Daniele et al. DIABETES
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
- (2014) Christopher D. Byrne et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes
- (2014) Mikkel Christensen et al. DIABETES
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Ectopic fat, insulin resistance and non-alcoholic fatty liver disease
- (2013) Christopher D. Byrne PROCEEDINGS OF THE NUTRITION SOCIETY
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Action and therapeutic potential of oxyntomodulin
- (2013) Alessandro Pocai Molecular Metabolism
- Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut
- (2010) Yukihiro Fujita et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver
- (2009) Giovanni Musso et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More